The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial

NCT06050577 on ClinicalTrials.gov · last registry update 2026-10-05

Closed to new participants; the 64 already enrolled are still being followed. Due to report 15 January 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Procollagen type 1 N-terminal propeptide (P1NP). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 7 June 2024 — 2 years so far. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status: ACTIVE_NOT_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Odense University Hospital
Sponsor type: Other
Enrollment: 64
Started: 2024-06-07
Primary completion: 2027-01-15 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-09-21	Reporting date moved	2026-01-15 → 2027-01-15 12 months later

Primary outcome

Procollagen type 1 N-terminal propeptide (P1NP)

Conditions studied

Type 2 Diabetes · Osteopenia

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.